-
EP1363884
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1363884
| EP1363884 - PYRIDINE-SUBSTITUTED BENZANILIDES AS POTASSIUM ION CHANNEL OPENERS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 05.04.2013 Database last updated on 28.03.2026 | Most recent event Tooltip | 05.04.2013 | Application deemed to be withdrawn | published on 08.05.2013 [2013/19] | Applicant(s) | For all designated states Icagen, Inc. Suite 460, 4222 Emperor Boulevard Durham, NC 27703 / US | [N/P] |
| Former [2003/48] | For all designated states Icagen, Inc. Suite 460, 4222 Emperor Boulevard Durham, NC 27703 / US | Inventor(s) | 01 /
MCNAUGHTON-SMITH, Grant 143 Walton's Creek Road Morrisville, NC 27560 / US | 02 /
FRITCH, Paul, Christopher 128 Castlewood Drive Cary, NC 27511 / US | 03 /
AMATO, George, Salvatore 101 Ashley Drive Cary, NC 27513 / US | [2004/10] |
| Former [2004/04] | 01 /
MCNAUGHTON-SMITH, Grant 143 Walton's Creek Road Morrisville, NC 27560 / US | ||
| 02 /
FRITCH, Paul, Christopher 5708-31 Windlestraw Drive Durham, NC 27713 / US | |||
| 03 /
AMATO, George, Salvatore 101 Ashley Drive Cary, NC 27513 / US | |||
| Former [2003/48] | 01 /
MCNAUGHTON-SMITH, Grant 2215-H Duck Pond Circle Morrisville, NC 27560 / US | ||
| 02 /
FRITCH, Paul, Christopher 5708-31 Windlestraw Drive Durham, NC 27713 / US | |||
| 03 /
AMATO, George, Salvatore 101 Ashley Drive Cary, NC 27513 / US | Representative(s) | Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | [2012/32] |
| Former [2012/11] | Lane, Graham Mark Hamilton Pfizer European Patent Department 23-25, avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | ||
| Former [2003/48] | Harrison Goddard Foote Belgrave Hall Belgrave Street Leeds LS2 8DD / GB | Application number, filing date | 02704333.0 | 01.02.2002 | [2003/48] | WO2002US03061 | Priority number, date | US20010776791 | 02.02.2001 Original published format: US 776791 | [2003/48] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO02062295 | Date: | 15.08.2002 | Language: | EN | [2002/33] | Type: | A2 Application without search report | No.: | EP1363884 | Date: | 26.11.2003 | Language: | EN | The application published by WIPO in one of the EPO official languages on 15.08.2002 takes the place of the publication of the European patent application. | [2003/48] | Search report(s) | International search report - published on: | US | 03.07.2003 | (Supplementary) European search report - dispatched on: | EP | 11.02.2005 | Classification | IPC: | C07D213/75, C07D401/12, C07D405/12, C07D409/12, C07D417/12, A61K31/44, A61P25/00, A61P35/00 | [2005/13] | CPC: |
C07D213/75 (EP,US);
A61K31/00 (EP,US);
A61K31/44 (EP,US);
A61P25/00 (EP);
A61P35/00 (EP);
C07D213/12 (EP,US);
C07D231/12 (EP,US);
C07D233/56 (EP,US);
C07D249/08 (EP,US);
C07D401/12 (EP,US);
C07D405/12 (EP,US);
C07D409/12 (EP,US);
C07D417/12 (EP,US)
(-)
|
| Former IPC [2003/48] | C07D213/02 | Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/48] | Extension states | AL | 22.08.2003 | LT | 22.08.2003 | LV | 22.08.2003 | MK | 22.08.2003 | RO | 22.08.2003 | SI | 22.08.2003 | Title | German: | PYRIDINSUBSTITUIERTE BENZANILIDE ALS KALIUMIONENKANALÖFFNER | [2003/48] | English: | PYRIDINE-SUBSTITUTED BENZANILIDES AS POTASSIUM ION CHANNEL OPENERS | [2003/48] | French: | BENZANILIDES A SUBSTITUTION PYRIDINE UTILISES COMME OUVREURS DE CANAUX IONIQUES DE POTASSIUM | [2003/48] | Entry into regional phase | 22.08.2003 | National basic fee paid | 22.08.2003 | Search fee paid | 22.08.2003 | Designation fee(s) paid | 22.08.2003 | Examination fee paid | Examination procedure | 28.08.2002 | Request for preliminary examination filed International Preliminary Examining Authority: US | 22.08.2003 | Amendment by applicant (claims and/or description) | 22.08.2003 | Examination requested [2003/48] | 02.02.2009 | Despatch of a communication from the examining division (Time limit: M06) | 11.06.2009 | Reply to a communication from the examining division | 14.12.2011 | Despatch of a communication from the examining division (Time limit: M04) | 03.05.2012 | Application deemed to be withdrawn, date of legal effect [2013/19] | 21.12.2012 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2013/19] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 02.02.2009 | Fees paid | Renewal fee | 22.08.2003 | Renewal fee patent year 03 | 22.02.2005 | Renewal fee patent year 04 | 27.02.2006 | Renewal fee patent year 05 | 27.02.2007 | Renewal fee patent year 06 | 25.02.2008 | Renewal fee patent year 07 | 09.02.2009 | Renewal fee patent year 08 | 08.02.2010 | Renewal fee patent year 09 | 08.02.2011 | Renewal fee patent year 10 | 07.02.2012 | Renewal fee patent year 11 | Penalty fee | Additional fee for renewal fee | 28.02.2013 | 12 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [PX] WO0110380 (ICAGEN INC et al.) [PX] 1,22 * claims 1, 9 and 23 and examples *;; claims 1,9,23 * | [PX] WO0121596 (ASTRAZENECA AB et al.) [PX] 1,22 * examples 565, 583 and 613 , page 266, lines 26-29 and claims 1 and 23 * | [PX] WO0155115 (CYTOVIA INC et al.) [PX] 1,22 * example 68; claims 42,45 * | [E] WO03004467 (AGOURON PHARMA et al.) [E] 1,22 * page 135, example 281, claims 1 and 24 * | [E] WO03020722 (BOEHRINGER INGELHEIM PHARMA et al.) [E] 1,22 * page 63, example 159; claims 1 and 8 * |